Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms, Unknown Primary × ivosidenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Leukemia, Myeloid, Acute 23 Myelodysplastic Syndromes 6 Myeloproliferative Disorders 5 Glioma 4 Cholangiocarcinoma 4 Leukemia 3 Wilms Tumor 2 Sarcoma, Ewing 2 Sarcoma 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Recurrence 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Neoplasm Metastasis 2 Medulloblastoma 2 Lymphoma, Non-Hodgkin 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Hematologic Neoplasms 2 Ependymoma 2 Biliary Tract Neoplasms 2 Xanthogranuloma, Juvenile 1 Pancreatic Ductal Adenocarcinoma 1 Neoplasms, Unknown Primary 1 Neoplasm, Residual 1 Lymphoma, Follicular 1 IDH1-Mutated Malignancies 1 IDH1 Mutation Myeloid Neoplasms 1

Interventions

Carboplatin 11 Paclitaxel 10 Gemcitabine 10 Capecitabine 7 Irinotecan 6 Fluorouracil 5 Cisplatin 5 Radiotherapy 4 Oxaliplatin 4 Leucovorin 4 Filgrastim 3 Etoposide 3 Cyclophosphamide 3 Bevacizumab 3 pembrolizumab 2 etoposide phosphate 2 atezolizumab 2 Trastuzumab 2 Topotecan 2 Surveys and Questionnaires 2 Peripheral Blood Stem Cell Transplantation 2 Magnetic Resonance Spectroscopy 2 Genetic Testing 2 FAPI-46 2 Erlotinib Hydrochloride 2 Docetaxel 2 CP protocol 2 Amifostine 2 Albumin-Bound Paclitaxel 2 zenocutuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡